Francesca Barone
Chief Scientific Officer Candel Therapeutics
Dr. Francesca Barone serves as Chief Scientific Officer at Candel Therapeutics. She oversees scientific discovery, the development of our novel viral immunotherapies and our biomarker strategy across our broad clinical portfolio. Dr. Barone previously served as Vice President and Head of Experimental Medicine at Flagship Pioneering’s Kintai Therapeutics, now Senda Biosciences. She has previously designed experimental medicine clinical trials to support rigorous decision-making across various programs and indications.
Before joining the industry, Dr. Barone held the academic position of Reader in Translational Rheumatology and Academic Director of Business Engagement for the College of Medical and Dental Sciences at the University of Birmingham. While there, she was also the Director of the laboratories for Immuno-phenotyping in the Institute of Translational Medicine. Dr. Barone earned her M.D. and completed a specialization in Rheumatology from the University of Rome, Sapienza, with merit and her Ph.D. from King’s College London.
Seminars
- Outlining a strategy for integrating diverse data streams, from molecular biomarkers to advanced imaging, to create a unified view of patient response
- Discussing how real-time insights from biomarkers and imaging can inform dynamic adjustments to drug dosage and treatment schedules, moving beyond traditional safety metrics
- Exploring how this integrated approach can provide a more robust and evidence-based foundation for making critical decisions about advancing the drug to a larger trial
- Join this workshop to deepen your understanding of how omics approaches and molecular subtyping are used to stratify glioblastoma patients and define target populations for new therapies
- Examining the strategic integration of multi-omics including genomics, transcriptomics, proteomics and epigenomics for a more comprehensive and clinically actionable GBM classification system
- Identifying and validating specific molecular features as robust markers for defining GBM subtypes with prognostic and predictive value
- Leveraging molecular subtyping further down the line in development to design biomarker-driven clinical trials to enrich patient experience and improve trial efficiency
- Identifying and validating novel biomarkers with a focus on their identification in discovery
- Looking towards personalized GBM treatment where therapy selection is guided by a patient’s molecular profile
- Addressing the lack of analysis of molecular data in current enrolment protocols for GBM trials
- Discussing strategies to incorporate biomarker-based enrolment given the rise of personalized therapies
- Establishing the efficacy of targeted treatments in recurrent GBM to accelerate the delivery of peronalized therapies
